Marcel Imwinkelried appointed as new CEO
Siegfried AG / Key word(s): Personnel
Marcel Imwinkelried appointed as new CEO
10-Jul-2024 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this
announcement.
____________________________________________________________
The Board of Directors of Siegfried Holding AG has appointed
Marcel Imwinkelried as the new CEO with effect as of September 1,
2024. He will succeed Reto Suter, who has been leading the
Siegfried Group as CEO ad interim since May 1, 2024, and will now
focus again on his role as CFO.
Marcel Imwinkelried (1967) joined the Siegfried Group in January
2021 as Multi-Site Head for the Drug Products sites in Barberà
del Vallès and El Masnou (Barcelona) and Irvine (California) and
was appointed Chief Operating Officer Drug Products in October
2021. Previously, he had worked for Novartis since 2005 in
various roles with increasing responsibility and was appointed
Global Head Technical Operations Solids in 2018.
Andreas Casutt, Chairman of the Board of Directors: "Over the
past three months, we have conducted intensive interviews with
qualified external and internal candidates. Marcel impressed us
not only with his professional track record, but also with his
personality and strong leadership skills. As COO of our Drug
Products division and a member of the Executive Board, he has
already made significant contributions to Siegfried's success
over the past three years. I am convinced that under his
leadership Siegfried will continue its journey of growth."
Contact
Financial Analysts: Media:
Dr. Reto Suter Peter Stierli
CEO ad interim and CFO Head Corporate Communications
reto.suter@siegfried.ch peter.stierli@siegfried.ch
Tel. +41 62 746 11 35 Tel. +41 62 746 15 51
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
About Siegfried
The Siegfried Group is a global life sciences company with sites
in Switzerland, Germany, Spain, France, Malta, the USA and China.
In 2023, the company achieved sales of CHF 1.272 billion and
employed on 31.12.2023 more than 3700 people at twelve sites on
three continents. Siegfried Holding AG is publicly listed on the
SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in manufacturing pharmaceutical APIs (and
their intermediates) as well as drug products (tablets, capsules,
sterile vials, ampoules, cartridges and ointments) for the
pharmaceutical industry and provides development services.
Cautionary Statements Regarding Forward-Looking Statements
This media release includes statements concerning the future.
They are based on assumptions and expectations that may prove to
be wrong. They should be considered with due caution as, by
definition, they contain known and unknown risks, insecurities
and other factors which could result in a difference in the
actual results, financial situation, developments or the success
of Siegfried Holding AG or Siegfried Group from the explicit or
implicit assumptions made in these statements.
expect more
Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland
+41 62 746 11 11
info@siegfried.ch
www.siegfried.ch
____________________________________________________________
End of Inside Information
____________________________________________________________
Language: English
Company: Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen
Switzerland
Phone: +41 62 746 11 11
E-mail: info@siegfried.ch
Internet: https://www.siegfried.ch
ISIN: CH0014284498
Listed: SIX Swiss Exchange
EQS News ID: 1942461
End of Announcement EQS News Service
____________________________________________________________
1942461 10-Jul-2024 CET/CEST